New targeted radiation therapy aims to improve stem cell transplants for tough myeloma
NCT ID NCT04579523
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepare the body for the transplant. The study will enroll 30 patients with newly diagnosed or relapsed/refractory high-risk myeloma to find the safest dose and see how well the disease responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Astatine-211-labeled anti-CD38 monoclonal antibody (OKT10-B10)
- What this could lead to
- If it works, this could offer a more targeted way to kill myeloma cells before a donor stem cell transplant, potentially improving outcomes for patients with high-risk disease.
- What could go wrong
- This is a very early phase I trial with only 30 participants, so safety and dosing are still being determined. The treatment involves strong chemotherapy and radiation, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- A One-Shot gene therapy could take on incurable blood cancer
- New PET tracer could sharpen diagnosis of blood cancers
- Web tool aims to empower rare cancer patients in genomic choices